Quick answer: At ARDD 2026, the world’s leading longevity research meeting held October 1-3 at Harvard, regulators, Big Pharma and scientists agreed on a new standard: longevity therapies must prove measurable benefits in humans, not just longer mouse lives.

The ARDD 2026 longevity pivot means intrinsic capacity scores, functional endpoints like VO2 max and aging clocks are the measures that count.

What happened at ARDD 2026

The 13th Aging Research and Drug Discovery meeting ran October 1-3, 2026, at the David Rubenstein Treehouse at Harvard, organized by Insilico Medicine. Attendees included Novartis, Eli Lilly, Pfizer, Takeda, GSK, AstraZeneca and Novo Nordisk, alongside FDA officials and 11 XPRIZE Healthspan finalist teams.

The opening morning set the tone.

Dr George Daley, Dean of Harvard Medical School’s Faculty of Medicine, said the field must be built on science and clinical rigor, citing a woman’s death at a New York wellness center after air entered her IV catheter. The science could transform later life, which is exactly why the bar must be high. (longevity.technology)

Admiral Brian Christine, Assistant Secretary for Health at the US Department of Health and Human Services, framed the policy case as prevention over reaction.

His test: is what we are doing actually making people healthier? He admitted patients are moving faster than institutions, with biological-age tests and peptides surging ahead of the evidence.

Dr Andrew Brack of ARPA-H described the plumbing. There is currently no regulatory path for measuring efficacy in a way that would let the FDA approve therapeutics targeting aging, so his PROSPR program, a five-year, $144 million effort, is building it.

PROSPR aims for 20 outcomes harmonized into intrinsic capacity scores stratified by gender and age, plus an at-home test kit, working toward a qualified Clinical Outcome Assessment the whole industry can use. Cambrian Bio also received up to $30.8 million under PROSPR to advance an mTORC1-selective inhibitor aimed at improving intrinsic capacity in older people.

ARDD co-chair Morten Scheibye-Knudsen said the focus reflects the ARDD 2026 longevity theme: a shift away from lifespan as the goal.

The aim now is preserving cognition, mobility, metabolic resilience and independence in later life.

Why the ARDD 2026 longevity pivot changes the rules

For a decade, the field’s currency was mouse lifespan plus biomarker movement. A compound that extended median mouse lifespan made headlines; whether it did anything for a human was speculative.

The FDA’s framework runs on three words: how a patient feels, functions and survives. A biological-age clock ticking down is a surrogate biomarker, not a clinical endpoint, and will not carry an approval on its own. (FDA)

Bottom line: no medicine is currently FDA-approved specifically to slow aging or extend lifespan. A conference talk describes early research; proof of benefit requires rigorous human studies and regulatory review.

The human-outcome measures taking shape

Three kinds of measures kept surfacing across the ARDD 2026 longevity sessions:

1. Intrinsic capacity

What a person can still do physically and mentally, being turned into a standardized trial endpoint by ARPA-H’s PROSPR: 20 harmonized outcomes, stratified by age and sex, with an at-home test kit.

2. Functional endpoints

Walk tests, VO2 max, grip strength, cognitive batteries. The FDA already accepts these elsewhere, and they map onto what older people care about: staying independent.

3. Aging clocks

Epigenetic and proteomic clocks keep improving at estimating biological age.

But a September 2026 rentosertib analysis found lower protein-based biological-age estimates in treated pulmonary fibrosis patients, though the clocks could not separate effects on aging from effects of treating the lung disease, and the trial flagged liver toxicity. A biomarker change alone cannot establish that a treatment improves health or survival. (More detail: aging clocks and the rentosertib story.)

What this means for your personal longevity protocol

The ARDD 2026 longevity message for biohackers cuts two ways: the field is maturing, but most circulating longevity advice is still unproven in humans.

No intervention has cleared the human-outcomes bar.

Metformin and rapamycin, the two most popular off-label candidates, carry adverse effects, and definitive evidence that they extend healthy human lifespan is lacking. Neither should be used solely for longevity without medical guidance or a regulated trial.

What already moves human endpoints: exercise that builds VO2 max and strength, sleep, nutrition, blood pressure control. These track intrinsic capacity directly.

Four questions to ask before trying any longevity therapy

• What human outcome was measured, and for how long? A 12-week biomarker shift is not a healthspan result.
• Clinical endpoint or only a biomarker? Function, disease onset and survival count. A clock score alone does not.
• Randomized trial or something weaker? Conference talks and mouse studies are starting points, not conclusions.
• What are the known harms? Preventive treatments may be used for years by healthy people.

The throughline of the ARDD 2026 longevity agenda is clear: the next breakthroughs will be proven in people, in how they feel, function and survive, not just in mice.

FAQ: ARDD 2026 longevity edition

Can a better biological-age score prove a therapy works?
No. The FDA requires evidence that changing the measurement reliably predicts a specific clinical benefit.

When will the FDA accept “aging” as an indication?
There is no timeline. The agency approves drugs based on measured improvements in how patients feel, function or survive, not on aging as a concept.

Health disclaimer: This article is for informational purposes only and is not medical advice.

Longevity interventions, including off-label drugs, peptides and supplements, carry real risks. Talk to a qualified physician before changing your health regimen or trying an experimental therapy. This site does not diagnose, treat or prescribe.